Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Core Viewpoint - Univest Securities, LLC has successfully closed a registered direct offering for Qualigen Therapeutics, Inc., raising approximately $3.46 million through the sale of common stock and pre-funded warrants [1][3]. Group 1: Offering Details - The offering consists of 14,724,058 shares of common stock priced at $0.130 per share, along with pre-funded warrants exercisable for 11,972,754 shares [1][2]. - The purchase price for each pre-funded warrant is set at $0.129 per share, with an exercise price of $0.001 per share [2]. Group 2: Financial Proceeds - The total gross proceeds from the offering amount to approximately $3.46 million [3]. Group 3: Regulatory Compliance - The offering was conducted under a shelf registration statement on Form S-1, which was originally filed with the SEC on June 13, 2023, and became effective on September 4, 2024 [4]. Group 4: Company Background - Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, with investigational compounds targeting cancer cell proliferation [7].